Related Experiment Video
Updated: Jun 22, 2025
12:01
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
10.7K
Mechanistic Insight into Intestinal α-Synuclein Aggregation in Parkinson's Disease Using a Laser-Printed
Julia M Balsamo1, Keren Zhou2,3, Vinay Kammarchedu2,3
1Department of Chemistry, University of California, Irvine, California 92617, United States.
ACS Chemical Neuroscience
|July 3, 2024
Summary
Parkinson's disease may start in the gut. Dietary compounds like dihydrocaffeic acid and caffeic acid show promise in preventing alpha-synuclein aggregation and dopamine oxidation, potentially offering new therapeutic avenues.
Area of Science:
- Neuroscience
- Gastroenterology
- Biochemistry
Background:
- Parkinson's disease (PD) is linked to alpha-synuclein aggregation and dopamine depletion.
- Alpha-synuclein aggregates accumulate in the gut years before motor symptoms, potentially originating in enteroendocrine cells.
- Enteroendocrine cells, which express dopamine and interact with gut bacteria and the nervous system, are implicated in PD pathology.
Purpose of the Study:
- To investigate the gut as a potential origin of Parkinson's disease.
- To explore dietary compounds as inhibitors of alpha-synuclein aggregation and dopamine oxidation in the gut.
- To develop novel tools for monitoring alpha-synuclein aggregation and dopamine levels.
Main Methods:
- Development of a laser-induced graphene-based electrochemical sensor chip for real-time tracking of alpha-synuclein aggregation and dopamine levels.
- Evaluation of diet-derived catechols (dihydrocaffeic acid, caffeic acid) as potential inhibitors.
- In vitro testing of catechols in STC-1 enteroendocrine cells.
Main Results:
- The developed sensor chip successfully tracked alpha-synuclein aggregation and dopamine levels.
- Dihydrocaffeic acid and caffeic acid were found to inhibit dopamine oxidation.
- These dietary catechols demonstrated inhibition of alpha-synuclein aggregation in enteroendocrine cells.
Conclusions:
- The gut, particularly enteroendocrine cells, may be a primary site for Parkinson's disease initiation.
- Dietary catechols show potential as therapeutic agents by inhibiting key pathological processes in the gut.
- These findings open new avenues for Parkinson's disease therapeutics targeting the gut environment and functional foods.
